Suppression of inflammatory arthritis in human serum paraoxonase 1 transgenic mice

Christina Charles-Schoeman,Aldons J Lusis,Victor Grijalva,Xiaoyan Wang,Srinivasa T Reddy,Yuen Yin Lee,Asokan Devarajan,Ernest Brahn,Christy Montano,Jennifer Wang,Diana M Shih,Ani Shahbazian

doi:10.1038/s41598-020-74016-w

Christina Charles-Schoeman, Aldons J Lusis + Show 10 more

Open Access

https://doi.org/10.1038/s41598-020-74016-w

Copy DOI

Abstract

Paraoxonase 1(PON1) is an HDL-associated protein, which metabolizes inflammatory, oxidized lipids associated with atherosclerotic plaque development. Because oxidized lipid mediators have also been implicated in the pathogenesis of rheumatoid arthritis (RA), we evaluated the role of PON1 in murine inflammatory arthritis. K/BxN serum transfer (STIA) or collagen antibody transfer (CAIA) was used for arthritis induction in B6 mice homozygous for the PON1 human transgene [PON1Tg], PON1 knock-out mice [PON1KO], and wild type littermate control mice [WT]. Experiments were also performed in K/BxN mice with chronic arthritis, and in RA patients and healthy controls. Arthritis activity in K/BxN mice was associated with a marked dyslipidemia, lower PON1 activity and higher bioactive lipid mediators (BLM), as well as a dysregulated hepatic lipid gene expression profile. Higher serum PON1 activity correlated with lower BLM and lower arthritis activity in both K/BxN mice and RA patients. Overexpression of the human PON1 transgene was associated with reduced inflammatory arthritis, which correlated strongly with higher circulating PON1 activity, upregulation of the hepatic glutathione pathway, and reduction of circulating BLM. These results implicate PON1 as a potential novel therapeutic target for joint disease in RA with potential for vascular benefit, which warrants further investigation.

Highlights

Paraoxonase 1(PON1) is an high-density lipoproteins (HDL)-associated protein, which metabolizes inflammatory, oxidized lipids associated with atherosclerotic plaque development
We demonstrate that overexpression of the human PON1 transgene (Tg) improves the dyslipidemia in arthritic mice, preventing increases in bioactive lipid mediators (BLM) with arthritis induction and decreasing arthritis activity and damage
K/BxN arthritis at 21 weeks was associated with reductions in total and HDL cholesterol (HDL-C) levels, similar to reports in active rheumatoid arthritis (RA) patients[15] More arthritic males had lower cholesterol levels compared to less arthritic females, and higher arthritic scores correlated significantly with lower cholesterol levels (Fig. 1A)

Summary

Introduction

Paraoxonase 1(PON1) is an HDL-associated protein, which metabolizes inflammatory, oxidized lipids associated with atherosclerotic plaque development. Arthritis activity in K/BxN mice was associated with a marked dyslipidemia, lower PON1 activity and higher bioactive lipid mediators (BLM), as well as a dysregulated hepatic lipid gene expression profile. Overexpression of the human PON1 transgene was associated with reduced inflammatory arthritis, which correlated strongly with higher circulating PON1 activity, upregulation of the hepatic glutathione pathway, and reduction of circulating BLM. These results implicate PON1 as a potential novel therapeutic target for joint disease in RA with potential for vascular benefit, which warrants further investigation. We first describe a marked dyslipidemia involving abnormalities in hepatic lipid metabolism, suppression of circulating PON1 activity and high BLM in the K/BxN mouse model of RA.

Methods

Results

Conclusion